Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives $17.67 Consensus Price Target from Analysts

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has earned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $17.6667.

A number of brokerages have issued reports on AUPH. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. Bloom Burton raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. Wall Street Zen downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Friday, August 7th.

Aurinia Pharmaceuticals Price Performance

NASDAQ:AUPH opened at $16.25 on Thursday. Aurinia Pharmaceuticals has a one year low of $10.34 and a one year high of $19.25. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42. The stock has a market cap of $2.16 billion, a PE ratio of 7.10 and a beta of 1.40. The stock has a 50 day moving average price of $15.79 and a 200 day moving average price of $15.60.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. The firm had revenue of $58.57 million for the quarter, compared to the consensus estimate of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. Equities research analysts expect that Aurinia Pharmaceuticals will post 0.79 EPS for the current fiscal year.

Institutional Trading of Aurinia Pharmaceuticals

Several institutional investors have recently made changes to their positions in AUPH. BOK Financial Private Wealth Inc. purchased a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $32,000. Nykredit A S purchased a new stake in Aurinia Pharmaceuticals in the second quarter valued at $35,000. Global Retirement Partners LLC purchased a new stake in Aurinia Pharmaceuticals in the second quarter valued at $41,000. Quantbot Technologies LP acquired a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $45,000. Finally, Allworth Financial LP acquired a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $56,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.